

Anti-Siglec-2/CD22 Antibody (Inotuzumab)

Introduction

Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody targeting human CD22. Inotuzumab is linked to the toxin ozogamicin as an antibody-active molecule conjugate (ADC). Inotuzumab is being studied in acute lymphoblastic leukemia and non-Hodgkin's lymphoma.

Product parameters

Alternative Names	BESPONSA, CMC-544
Target Accession	P20273
Target	Siglec-2 / CD22
CAS number	635715-01-4
Molecular Weight	146.48 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	-
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μ M filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

